| Chapter 1 - Gastro-intestinal System |
| 1.1 Dyspepsia & gastro-oesophageal reflux disease |
| 1.2 Antispasmodics |
| 1.3 Antisecretory drugs |
| 1.3.5 Proton pump inhibitors (PPI) |
| 1.3.5 Helicobacter pylori eradication |
| 1.4 Acute diarrhoea |
| 1.5 Chronic bowel disorders |
| Guidance on assessing dehydration in children under 5 years |
| 1.6 Laxatives |
| 1.7 Local preparations for anal and rectal disorders |
| Chapter 2 - Cardiovascular System |
| 2.1 Positive inotropic drugs |
| 2.2 Diuretics |
| 2.3 Anti-arrhythmic drugs |
| 2.4 Beta-adrenoreceptor blocking drugs |
| 2.5 Drugs affecting the renin-angiotensin system |
| 2.5 Summary of Antihypertensive Drug Treatment |
| 2.5 Care Pathway for Hypertension |
| 2.5 Prescribing Guidelines for Heart Failure Guidance |
| 2.6 Nitrates, CCBs and potassium channel activators |
| 2.6 Primary Care Guidelines for drug treatment of Chronic Stable Angina Pectoris |
| 2.6.3 Other antianginal drugs |
| 2.6.4 Peripheral vasodilators and related drugs |
| 2.8 Anticoagulant drugs |
| 2.8.2 Oral anticoagulants |
| 2.8.2 Drug Interactions for Apixaban, Dabigatran, Edoxaban and Rivaroxaban |
| 2.8.2 Decision aid for patients requiring stroke prevention in AF |
| 2.8.2 Reducing the risk of stroke in Atrial Fibrillation - NICE CG180 (including decision aid) |
| 2.8.2 NOAC Implementation priorities |
| 2.9 Antiplatelet drugs |
| 2.12 Lipid regulation |
| 2.12 Lipid regulating drugs |
| Chapter 3 - Respiratory System |
| 3 Introduction |
| Asthma Inhaler Pathways |
| Asthma Step-down Guides |
| Summary of recently introduced inhalers and their equivalents |
| 3.1 Bronchodilators |
| 3.2 Corticosteroids |
| 3.3.2 Leukotriene receptor antagonists |
| Guidance for managing COPD |
| 3.4.1 - Antihistamines |
| 3.7 - Mucolytics |
| Chapter 4 - Central Nervous System |
| 4.1 - Hypnotics and anxiolytics |
| 4.2 - Drugs used in psychoses and related disorders |
| 4.2.3 - Antimanic drugs |
| 4.3 - Antidepressants |
| 4.5 - CNS stimulants and drugs for ADHD |
| 4.5.1 - Drugs used in the treatment of obesity |
| 4.7 - Analgesics |
| 4.7.3 - Neuropathic pain |
| 4.7.4 - Antimigraine drugs |
| 4.8.1 - Epilepsy |
| 4.8.2 - Drugs used in status epilepticus |
| 4.10 - Drugs used in substance dependence |
| 4.11 - Drugs for dementia |
| Chapter 5 - Infections |
| link to Management of Infection Guidance for Primary Care |
| 5.1 - Antibacterial drugs |
| 5.2 - Antifungal drugs |
| 5.3 - Antiviral drugs |
| Chapter 6 - Endocrine System |
| 6.1 - Drugs used in diabetes |
| 6.1.1 - Insulins |
| 6.1.2 - Drugs used in diabetes |
| 6.1 - Guidance on the use of Blood Glucose Testing Strips |
| 6.2 - Thyroid and anti-thyroid drugs |
| 6.3 - Corticosteriods |
| 6.4.1 - Hormone Replacement Therapy |
| 6.4.2 - Male sex hormones and antagonists |
| 6.5.2 - Posterior pituitary hormones and antagonists |
| 6.6 - Drugs affecting bone metabolism |
| 6.6 - Protocol for primary care management of patients prescribed PROLIA® (Denosumab) for prevention of fractures |
| Chapter 7 - Obstetrics, Gynaecology and Urinary Tract Disorders |
| 7.2 - Treatment of vaginal and vulval conditions |
| 7.3 - Contraceptives |
| 7.3 - Consillient Pill Equivalences and VTE Risk |
| 7.4.1 - Drugs for urinary retention |
| 7.4.2 - Drugs for urinary frequency, enuresis and incontinence |
| 7.4.5 - Drugs for erectile dysfunction |
| 7.4.6 - Drugs for premature ejaculation |
| Chapter 8 - Malignant Disease and Immunosuppression |
| 8.3 - Sex Hormones and Hormone Antagonists in Malignant Disease |
| Chapter 9 - Nutrition and Blood |
| 9.1 - Anaemias and some other blood disorders |
| 9.2 - Fluids and electrolytes |
| 9.5 - Minerals |
| 9.6 - Vitamins |
| Chapter 10 - Musculoskeletal and joint diseases |
| 10.1 – Drugs used in Rheumatic Disease and Gout |
| 10.1 – Treatment of Gout |
| 10.1- Management of Osteoarthritis |
| Chapter 11 – Eye |
| 11.3 – Anti-infective eye preparations |
| 11.4 – Corticosteriods and other anti-inflammatory preparations |
| 11.5 – Mydriatics and Cycloplegics |
| 11.6 – Treatment of Glaucoma |
| 11.8 – Miscellaneous ophthalmic preparations |
| Chapter 12 – Drugs acting on the Ear |
| 12.1 – Drugs acting on the Nose |
| 12.2 – Nasal Allergy |
| 12.3 – Drugs acting on the Oropharynx |
| Chapter 13 – Skin |
| 13.2 – Emollient and barrier preparations guidance |
| 13.2.1 – Emollients |
| 3.2.1.1 – Emollient bath additives and shower preparations |
| 13.3 – Local Anaesthetics and Antipruritics |
| 13.4 – Topical corticosteriods |
| 13.5 – Preparations for Eczema and Psoriasis |
| 13.6.1 – Topical preparations for acne |
| 13.6.2 – Oral preparations for acne |
| 13.8 – Photodamage |
| 13.10 –Anti-infective skin preparations |
| Chapter 15 – Anaesthesia |
| 15.1.7 – Antagonists for central and respiratory depression |
